Summary: Recent research has uncovered a potential link between immune system activity and mental health conditions such as schizophrenia, depression, and Alzheimer’s disease. Scientists employed Mendelian randomization to connect 29 immune-related proteins with seven neuropsychiatric disorders, implying that mental health issues might involve more than just the brain.
Approximately 20 of these proteins are already targets for existing medications designed to treat other illnesses, which could lead to new therapeutic options. This challenges the traditional notion that mental health is solely a brain-related issue, suggesting it’s influenced by the entire body and its immune functions.
Key Facts:
- Immune Involvement Found: 29 immune proteins were associated with seven mental health conditions.
- Drug Target Potential: 20 of these proteins are already targeted by drugs for other conditions.
- Rethinking Mental Health: These findings challenge the conventional focus on the brain, suggesting a whole-body involvement.
Source: University of Bristol
Conditions like depression and schizophrenia affect roughly 1 in 4 people during their lifetime, yet the underlying mechanisms remain poorly understood.
This new study, led by researchers at the University of Bristol, links the immune response to various conditions, including schizophrenia, Alzheimer’s disease, depression, and bipolar disorder.
The study indicates that physical factors beyond the brain may influence mental health and could lead to improved treatment options.
Currently, many individuals with depression or schizophrenia receive medications targeting neurotransmitters like serotonin and dopamine. However, about a third of these patients do not respond positively to these treatments, hinting at the possibility of other underlying factors.
The research, which involved Dr. Christina Dardani and Professor Golam Khandaker at Bristol’s MRC Integrative Epidemiology Unit, utilized Mendelian randomization. This approach analyzes genetic information from large datasets to determine if immune proteins might be linked to the seven neuropsychiatric conditions studied.
They examined how 735 immune response-related proteins found in human blood relate to depression, anxiety, schizophrenia, bipolar disorder, Alzheimer’s disease, autism, and ADHD.
From the identified biomarkers, researchers suggested a potential causal role for 29 proteins across these conditions, with 20 being plausible targets for existing drugs.
These biomarkers may eventually contribute to new treatments in the realm of mental health.
These results indicate a shift in understanding the causes of neuropsychiatric conditions, which have typically been attributed to neurotransmitter imbalances. The new findings propose that immune system overactivity might also play a role in mental health disorders.
Golam Khandaker, a professor of Psychiatry and Immunology, remarked that the study suggests inflammation—both in the brain and body—could impact the risk of developing mental health conditions.
He noted that this research challenges the outdated division between body and mind, urging a more holistic perspective on conditions like depression and schizophrenia.
The next steps involve further investigating the biomarkers identified in this genetic analysis using various approaches, including health record analysis, animal studies, and initial clinical trials, to deepen the understanding of how inflammation might influence mental health symptoms and explore therapeutic possibilities—such as whether altering immune pathways can alleviate these issues.
Funding: This investigation received support from a Medical Research Council program grant for immunopsychiatry directed by Professor Golam Khandaker and is part of the University of Bristol’s MRC IEU.
About this mental health research news
Author: Joanne Fryer
Source: University of Bristol
Contact: Joanne Fryer – University of Bristol
Image: Credit to Neuroscience News.
